Proteomics International Laboratories Ltd (ASX:PIQ) September 2024 Quarterly Activities Report
Date
10/21/2024 11:27:06 PM
(MENAFN- ABN Newswire)
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics and precision medicine is pleased to provide the following update on its business activities for the three months to 30 September 2024 and subsequent to the period end.
The quarterly report updates are listed below:
- World first blood test for esophageal cancer shows 94% accuracy: results demonstrated outstanding diagnostic performance for identifying patients with esophageal adenocarcinoma (EAC) in a clinical validation study.
- Groundbreaking study on PromarkerD and type 1 diabetes and kidney health: results show PromarkerD demonstrated high accuracy in predicting chronic kidney disease in this new group of patients (all previous applications were directed at patients with type 2 diabetes).
- Update on commercialisation of PromarkerD: Proteomics International is targeting a US launch in H1 CY25, and an Australian launch in Q1 CY25 through a hybrid approach of traditional licensing and direct-to-consumer/patient (DTC/DTP) Go-to-Market strategies.
- PromarkerEndo and PromarkerEso tests advance
- Analytical Services: ISO 17025 certification successfully renewed following audit by National Association of Testing Authorities (NATA).
- Events and Marketing
- Financial and Corporate Highlights: Appointment of Dr James Williams as an independent nonexecutive director and deputy chair.
- Target share price catalysts FY25
*To view the Quarterly Report, please visit:
-p alt="Proteomics International Laboratories Ltd" src="https://media.abnnewswire.net/images/logos/37153en.png" style="float:left; height:15px; margin:5px; width:120px" />Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: ...
Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: ...
Andrew Williams
Public Relations
Profile Media
T: +61 412 614 125
E: ...
MENAFN21102024000111011020ID1108804636
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.